Use of NLRP3 Inflammasome Activity as a Disease Biomarker for Patient Stratification & the Design of Clinical Trials Testing NLRP3 Antagonists

Time: 2:30 pm
day: Day One


  • NLRP3 inflammasome response is able to early stratify septic patients gravity
  • A group of septic patients present a profound NLRP3 immunosuppression associated with their gravity
  • NLRP3 activity is as a biomarker to stratify patients and design clinical trials